What do we want to say exactly with "non-vertebral fractures"? (Or why not call things by their name?);¿Qué queremos decir exactamente con "fracturas no vertebrales"? (O ¿por qué no llamar a las cosas por su nombre?)

Revista Espanola de Enfermedades Metabolicas Oseas

Volumn 14, Issue 3, 2005, Pages 39-40

  Gomez De Tejada Romero M J ^b   Sosa Henriquez M ^a  

^a UNIVERSITY OF LAS PALMAS DE GRAN CANARIA   (Spain)

^b UNIVERSITY OF SEVILLE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DENSITOMETRY; EDITORIAL; FRACTURE; HUMERUS FRACTURE; MORBIDITY; MORTALITY; NON VERTEBRAL FRACTURE; OSTEOPOROSIS; RISK ASSESSMENT; RISK FACTOR; VERTEBRA FRACTURE;

EID: 21244495334     PISSN: 11328460     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1132-8460(05)72679-9     Document Type: Editorial

References (30)

1. Body JJ. Management of primary osteoporosis. Acta Clin Belg. 2002;57:277-83.
2. Reeve J, Silman A, on behalf of the EPOS Study Group. Epidemiology of Osteoporotic fractures in Europe: towards biologic mechanisms. The European Prospective Osteoporotic Study. Osteoporos Int. 1997; 7 Suppl 3:S78-83.
3. Naves Díaz M, Díaz López JB, Gómez Alonso C, Altadill Arregui A, Rodríguez Rebollar A, Cannata Andía JB. Estudio de incidencia de fracturas osteoporoticas en una cohorte mayor de 50 años durante un periode de 6 años de seguimiento. Med Clin (Barc). 2000;115:650-3.
4. Harrington JT, Ste-Marie LG, Brandi ML, Civitelli R, Fardellone P, Grauer A, et al. Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int. 2004;74:129-35.
5. Pasco JA, Kotowitz MA, Henry J, Sanders KM, Seeman E, Nicholson GC. Hormone therapy and risk of non-vertebral fracture: Geelong Osteoporosis Study. Osteoporos Int. 2004;15:434-8.
6. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. A Randomized Controlled Trial. JAMA. 1999;282:1344-52.
7. Chesnut III CH, Silverman S, Andriano K, Genant H, Gimona A, Harris S, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the Prevent Recurrence of Osteoporotic Fractures Study. Am J Med. 2000;109:267-76.
8. Wells G, Tugwell P, Shea B, Guyatt G, Peterson J, Zutaruk N, et al. V. Meta-analisis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocr Rev. 2002;23: 529-39.
9. Bauer DC, Black DM, Garnero P, Hochberg M, Ott S, Orloff J, et al. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate treated women: The Fracture Intervention Trial. J Bone Miner Res. 2004;19:1250-8.
10. Group for The Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA. 2002;288:321-33.
11. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. 1996;348:1535-41.
12. Cummings SR, Blank DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, et al. Effect of alendronate on risk of fractures in women with low bone density but without vertebral fractures. JAMA. 1998; 280;2077-82.
13. Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, et al. Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial. J Clin Endocrinol Metab. 2000; 85:4118-24.
14. Cauley JA, Black DM, Barrett-Connor E, Harris F, Shields K, Applegate W, et al. Effects of hormone replacement therapy on clinical fractures and height loss: The Heart and Estrogen/Progestin Replacement Study (HERS). Am J Med. 2001;110:442-50.
15. Ettinger B, Black D, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. Results from 3-year randomized clinical trial. JAMA. 1999;282:637-45.
16. Pols HAP, Feisenberg D, Hanley DA, Stepán J, Muñoz-Torres M, Wilkin TJ, et al. Multinational placebo-controlled, randomized trial of the effects of alendronate on bone mineral density and fractures risk in postmenopausal women with low bone mass: results of the FOSIT study. Osteoporos Int. 1999;9:461-8.
17. Karpf DB, Shapiro DR, Seeman E, Ensrud KE, Johnston CC, Adami S, et al. Prevention of nonvertebral fractures by alendronate. A meta-analysis. JAMA. 1997;277:1159-64.
18. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral densiry in postmenopausal women with osteoporosis. N Engl J Med. 2001; 344:1434-41.
19. Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med. 2004;350:459-68.
20. Delmas PD. Different effects of antiresorptive therapies on vertebral and non vertebral fractures in postmenopausal osteoporosis. Bone. 2002;30: 14-7.
21. Hochberg M. Preventing fractures in postmenopausal women with osteoporosis. A Review of recent controlled trials of antiresorptive agents. Drug Aging. 2000;17:317-30.
22. Wehren LE, Hosking D, Hochberg MC. Putting evidence-based medicine into clinical practice: comparing anti-resorptive agents for the treatment of osteoporosis. Curr Med Res Opin. 2004;20:525-31.
23. Eastell R, Reid DM, Compston J, Cooper C, Fogelman I, Francis RM, et al. Secundary prevention of osteoporosis: when should a non-vertebral fracture be a trigger for action? Q J Med. 2001;94:575-97.
24. Bauer DC, Mundy GR, Jamal SA, Black DM, Cauley JA, Ensrud KE, et al. Use of statins and fracture. Results of 4 prospective studies and cumulative meta-analysis of observational studies and controlled trials. Arch Intern Med. 2004;164:146-52.
25. Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C, The Osteoporotic Methodology Group and The Osteoporosis Research Advisory Group. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev. 2002;23:517-23.
26. Karpf DB, Shapiro DR, Seeman E, Ensrud KE, Johnston CC, Adami S, et al. Prevention of nonvertebral fractures by alendronate. JAMA. 1997; 277:1159-64.
27. Hallberg L, Rosenqvist AM, Kartous L, Löfman O, Wahlström O, Toss G. Health-related quality of life after osteoporotic fractures. Osteoporos Int. 2004 Mar 25 (Epub ahead of print). Disponible en: www.springerlink.com
28. Johnell O, Kanis JA, Oden A, Sernbo I, Redlund-Johnell I, Petterson C, et al. Mortality after osteoporotic fractures. Osteoporos Int. 2004;15:38-42.
29. Dolan P, Torgerson DJ. The cost of treating osteoporotic fractures in the United Kingdom female population. Osteoporos Int. 1998;8:611-7.
30. Compston JE. Pharmacological interventions for the prevention of vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: does site-especificity exist? Bone. 2000;27:765-8.